Neoadjuvant chemotherapy for triple-negative breast cancer： a meta-analysis with 7168 cases.pdfVIP

Neoadjuvantchemotherapyfortriple—-negative GuojingZhang，WanqingXie(Co—firstauthor)，ChaoLin。，ZhaozheLiu，LongXu，GuanzhongZhang， FangGuo，YalingHan，HongxinZheng，XiaodongXie DepartmentofOncology，TheGeneralHospitalofShenyangMilitaryRegion，Shenyang110840，China MolecularBiologyLaboratory ofTraditionalChineseMedicine，TheBasicMedicalCollegeofLiaoningUniversityof TraditionalChineseMedicine，Shenygang110032，China 0DepartmentofGynaecologyandObstetrics，ZhejiangChineseMedicalUniversityAffiliatedHospitalofWenzhou TraditionalChineseMedicine，W enzhou325000，China CardiovascularDiseaseInstitute，GeneralHospitalofShenyangMilitary Region，Shenyang110840，China Received：4November2013／Revised：25November2013／Accepted：15December2013 @HuazhongUniversityofScienceandTechnology2014 Abstract Objective：Thepathologicalcompleteresponse(pCR)ratesofneoadjuvantchemotherapy(NAC)inlriple．nega． rivebreastcancer(TNBC)wasreportedhigherthanthatinnon-TNBCbutrangedfrom12％l048％．pCRwasreportedtobe apredictorofIongoverallsurvivaIandexactpCRrateofNACinTNBCwouldgiveussomehintsonhowloireproveoutcomes ofTNBCpatients．Themeta．analysiswasconductedloestimatelhepCRrateofNACforTNBCthroughcontrastinglhepCR ratesofTNBCandnon—TNBClumorsinNAC．Methods：Studieswereselectedfr0mlhePubMeddatabaseandCochrane CollaborationLibrary．pCRrateswerecollectedingroupsofTNBCandnon．TNBClumors．ReviewManager4．2wasusedlo perf_ormforeslplotsandfunneIplots．Results：Theanalysisincluded22studieswith7168patients，IheaggregatepCRrate was29．5％inTNBCgroup，whichwas17．7％higherlhannon-TNBC．Thesummaryrelativerisk(RR)forpCRrateofTNBC groupwithlhalofnon．TNBCgroupwas2．55．NoobviousstatisticaIheterogeneityandpublicationbiaswasdetected．Conclu- sio，IThismeta．analysisdemonstratedlhalNACshowedahigherpCRrateinTNBClhannon．TNBC． Keywords neoadjuvantchemotherapy(NAC)；triple-negativebreastcancer(T